APA
Seyednasrollah F., Mahmoudian M., Rautakorpi L., Hirvonen O., Laitinen T., Jyrkkiö S. & Elo L. L. (20180522). Reply to Tuomas Mirtti and Tero Aittokallio's Letter to the Editor re: Fatemeh Seyednasrollah, Mehrad Mahmoudian, Liisa Rautakorpi, et al. How Reliable are Trial-based Prognostic Models in Real-world Patients with Metastatic Castration-resistant Prostate Cancer? Eur Urol. 2017;71:838-40. Clinical Utility of Trial-estimated Prognostic Models. : European urology.
Chicago
Seyednasrollah Fatemeh, Mahmoudian Mehrad, Rautakorpi Liisa, Hirvonen Outi, Laitinen Tarja, Jyrkkiö Sirkku and Elo Laura L. 20180522. Reply to Tuomas Mirtti and Tero Aittokallio's Letter to the Editor re: Fatemeh Seyednasrollah, Mehrad Mahmoudian, Liisa Rautakorpi, et al. How Reliable are Trial-based Prognostic Models in Real-world Patients with Metastatic Castration-resistant Prostate Cancer? Eur Urol. 2017;71:838-40. Clinical Utility of Trial-estimated Prognostic Models. : European urology.
Harvard
Seyednasrollah F., Mahmoudian M., Rautakorpi L., Hirvonen O., Laitinen T., Jyrkkiö S. and Elo L. L. (20180522). Reply to Tuomas Mirtti and Tero Aittokallio's Letter to the Editor re: Fatemeh Seyednasrollah, Mehrad Mahmoudian, Liisa Rautakorpi, et al. How Reliable are Trial-based Prognostic Models in Real-world Patients with Metastatic Castration-resistant Prostate Cancer? Eur Urol. 2017;71:838-40. Clinical Utility of Trial-estimated Prognostic Models. : European urology.
MLA
Seyednasrollah Fatemeh, Mahmoudian Mehrad, Rautakorpi Liisa, Hirvonen Outi, Laitinen Tarja, Jyrkkiö Sirkku and Elo Laura L. Reply to Tuomas Mirtti and Tero Aittokallio's Letter to the Editor re: Fatemeh Seyednasrollah, Mehrad Mahmoudian, Liisa Rautakorpi, et al. How Reliable are Trial-based Prognostic Models in Real-world Patients with Metastatic Castration-resistant Prostate Cancer? Eur Urol. 2017;71:838-40. Clinical Utility of Trial-estimated Prognostic Models. : European urology. 20180522.